09:47 AM EST - Acerus Pharmaceuticals Corporation : Reported its financial results for the three-month period ended September 30. Unless otherwise noted, all amounts are in U.S. dollars and are prepared in accordance with International Financial Reporting Standards. The company reported revenue of $0.5 million for the third quarter of 2020 compared to negative $0.2 million in the comparable period of 2019, reflecting the impact of new shipments of NATESTO® to the U.S. market in 2020. The company posted a net loss of $7.0 million, or $(0.01) per share, for the quarter compared to a loss of $4.6 million, or $(0.02) per share, in the third quarter of 2019. Acerus Pharmaceuticals Corporation
shares T.ASP are trading unchanged at $0.04.
